Conventional chemotherapy induces immunogenic cell death, supplies neoantigens, and depletes myeloid-derived suppressor cells; the combining of platinum doublets with PD-1/PD-L1 blockade in pre-treated NSCLC or urothelial cancer has raised response rates to the 20–30% range [77,78,79,80]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.